source
- Celea Therapeutics raises $180 million to advance next-generation IPF drug deupirfenidoneCelea Therapeutics, a PureTech Health spinout, announced a $180 million venture round to fund development of its next-generation idiopathic pulmonary fibrosis (IPF) therapy, deupirfenidone. The ro…
- Scribe Therapeutics files for Nasdaq IPO, testing market appetite for early-stage gene-editing firmsScribe Therapeutics announced it has filed a registration statement to list its shares on the Nasdaq, marking the company’s first step toward a public offering. The filing highlights the growing i…